Literature DB >> 27795556

Arsenic trioxide degrades NPM-ALK fusion protein and inhibits growth of ALK-positive anaplastic large cell lymphoma.

W Piao1, D Chau1, L M Yue1, Y-L Kwong1, E Tse1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27795556     DOI： 10.1038/leu.2016.311

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

Review 1.  Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.

Authors:  H G Drexler; S M Gignac; R von Wasielewski; M Werner; W G Dirks
Journal:  Leukemia       Date:  2000-09       Impact factor: 11.528

Review 2.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

3.  Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.

Authors:  Maria Paola Martelli; Ilaria Gionfriddo; Federica Mezzasoma; Francesca Milano; Sara Pierangeli; Floriana Mulas; Roberta Pacini; Alessia Tabarrini; Valentina Pettirossi; Roberta Rossi; Calogero Vetro; Lorenzo Brunetti; Paolo Sportoletti; Enrico Tiacci; Francesco Di Raimondo; Brunangelo Falini
Journal:  Blood       Date:  2015-03-20       Impact factor: 22.113

4.  PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.

Authors:  Marion Jeanne; Valérie Lallemand-Breitenbach; Omar Ferhi; Marcel Koken; Morgane Le Bras; Stéphanie Duffort; Laurent Peres; Caroline Berthier; Hassane Soilihi; Brian Raught; Hugues de Thé
Journal:  Cancer Cell       Date:  2010-07-13       Impact factor: 31.743

5.  Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target.

Authors:  Roberto Chiarle; William J Simmons; Honjying Cai; Girish Dhall; Alberto Zamo; Regina Raz; James G Karras; David E Levy; Giorgio Inghirami
Journal:  Nat Med       Date:  2005-05-15       Impact factor: 53.440

6.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.

Authors:  G Q Chen; X G Shi; W Tang; S M Xiong; J Zhu; X Cai; Z G Han; J H Ni; G Y Shi; P M Jia; M M Liu; K L He; C Niu; J Ma; P Zhang; T D Zhang; P Paul; T Naoe; K Kitamura; W Miller; S Waxman; Z Y Wang; H de The; S J Chen; Z Chen
Journal:  Blood       Date:  1997-05-01       Impact factor: 22.113

7.  ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.

Authors:  Kerry J Savage; Nancy Lee Harris; Julie M Vose; Fred Ullrich; Elaine S Jaffe; Joseph M Connors; Lisa Rimsza; Stefano A Pileri; Mukesh Chhanabhai; Randy D Gascoyne; James O Armitage; Dennis D Weisenburger
Journal:  Blood       Date:  2008-04-02       Impact factor: 22.113

8.  Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.

Authors:  Vivien Mak; Jeremey Hamm; Mukesh Chhanabhai; Tamara Shenkier; Richard Klasa; Laurie H Sehn; Diego Villa; Randy D Gascoyne; Joseph M Connors; Kerry J Savage
Journal:  J Clin Oncol       Date:  2013-04-22       Impact factor: 44.544

9.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

Authors:  S W Morris; M N Kirstein; M B Valentine; K G Dittmer; D N Shapiro; D L Saltman; A T Look
Journal:  Science       Date:  1994-03-04       Impact factor: 47.728

10.  Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity.

Authors:  Z Diaz; A Laurenzana; K K Mann; T A Bismar; H M Schipper; W H Miller
Journal:  Leukemia       Date:  2007-08-09       Impact factor: 11.528
View more
  5 in total

1.  Mitochondrial toxicity of organic arsenicals: membrane permeability transition pore opening and respiratory dysfunction.

Authors:  Xiao-Yang Fan; Lian Yuan; Can Wu; Yu-Jiao Liu; Feng-Lei Jiang; Yan-Jun Hu; Yi Liu
Journal:  Toxicol Res (Camb)       Date:  2017-12-19       Impact factor: 3.524

2.  Combination of arsenic trioxide and Dasatinib: a new strategy to treat Philadelphia chromosome-positive acute lymphoblastic leukaemia.

Authors:  Tao Wang; Chunyan Cheng; Lijun Peng; Mengqing Gao; Mengping Xi; Sophie Rousseaux; Saadi Khochbin; Jin Wang; Jianqing Mi
Journal:  J Cell Mol Med       Date:  2017-12-20       Impact factor: 5.310

Review 3.  PIN1 in Cell Cycle Control and Cancer.

Authors:  Chi-Wai Cheng; Eric Tse
Journal:  Front Pharmacol       Date:  2018-11-26       Impact factor: 5.810

Review 4.  Targeting PIN1 as a Therapeutic Approach for Hepatocellular Carcinoma.

Authors:  Chi-Wai Cheng; Eric Tse
Journal:  Front Cell Dev Biol       Date:  2020-01-15

5.  Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

Authors:  Kar-Tong Tan; Ling-Wen Ding; Qiao-Yang Sun; Zhen-Tang Lao; Wenwen Chien; Xi Ren; Jin-Fen Xiao; Xin Yi Loh; Liang Xu; Michael Lill; Anand Mayakonda; De-Chen Lin; Henry Yang; H Phillip Koeffler
Journal:  BMC Cancer       Date:  2018-10-01       Impact factor: 4.430
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.